LONDON, Oct 23 (Reuters) - An experimental Amgen AMGN.O
drug based on a tumour-killing virus was given a green light by
European regulators on Friday, paving the way for the novel
treatment's approval within a couple of months.
The decision is a further milestone for a technology that
has long fascinated scientists but has previously proved
difficult to harness.
The European Medicines Agency said its experts had
recommended approval of talimogene laherparepvec or "T-Vec" for
treating melanoma, making it another option among several new
drugs for fighting for the most deadly form of skin cancer.